MA53898B1 - Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament - Google Patents

Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament

Info

Publication number
MA53898B1
MA53898B1 MA53898A MA53898A MA53898B1 MA 53898 B1 MA53898 B1 MA 53898B1 MA 53898 A MA53898 A MA 53898A MA 53898 A MA53898 A MA 53898A MA 53898 B1 MA53898 B1 MA 53898B1
Authority
MA
Morocco
Prior art keywords
pyrazin
ylmethyl
medicine
morpholine derivatives
nr2b
Prior art date
Application number
MA53898A
Other languages
English (en)
Other versions
MA53898A (fr
Inventor
Riccardo Giovannini
Cornelia Dorner-Ciossek
Dieter Wiedenmayer
Angelo Ceci
Roland Pfau
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA53898A publication Critical patent/MA53898A/fr
Publication of MA53898B1 publication Critical patent/MA53898B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne de nouvelles 4-pyrazin-2-ylméthyl-morpholines de formule générale a, des procédés pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en thérapie, en particulier dans le traitement ou la prévention d'états associés à des propriétés de modulation allostérique négative de nr2b.
MA53898A 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament MA53898B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18200943 2018-10-17
PCT/EP2019/078027 WO2020079039A1 (fr) 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament

Publications (2)

Publication Number Publication Date
MA53898A MA53898A (fr) 2022-01-26
MA53898B1 true MA53898B1 (fr) 2023-03-31

Family

ID=63878518

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53898A MA53898B1 (fr) 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament

Country Status (38)

Country Link
US (3) US11166958B2 (fr)
EP (1) EP3867244B1 (fr)
JP (1) JP7093468B2 (fr)
KR (1) KR102840105B1 (fr)
CN (1) CN112888685B (fr)
AR (1) AR116711A1 (fr)
AU (1) AU2019362330B2 (fr)
BR (1) BR112021004993A2 (fr)
CA (1) CA3113308A1 (fr)
CL (1) CL2021000858A1 (fr)
CO (1) CO2021004612A2 (fr)
CR (1) CR20210184A (fr)
DK (1) DK3867244T3 (fr)
DO (1) DOP2021000069A (fr)
EA (1) EA202191014A1 (fr)
EC (1) ECSP21027009A (fr)
ES (1) ES2940184T3 (fr)
FI (1) FI3867244T3 (fr)
HR (1) HRP20230249T1 (fr)
HU (1) HUE061891T2 (fr)
IL (1) IL282142B2 (fr)
JO (1) JOP20210075B1 (fr)
LT (1) LT3867244T (fr)
MA (1) MA53898B1 (fr)
MX (1) MX2021004418A (fr)
MY (1) MY205127A (fr)
NZ (1) NZ773672A (fr)
PE (1) PE20211278A1 (fr)
PH (1) PH12021550834A1 (fr)
PL (1) PL3867244T3 (fr)
PT (1) PT3867244T (fr)
RS (1) RS63988B1 (fr)
SA (1) SA521421756B1 (fr)
SG (1) SG11202103806VA (fr)
SI (1) SI3867244T1 (fr)
TW (1) TWI828779B (fr)
UA (1) UA128408C2 (fr)
WO (1) WO2020079039A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376258B2 (en) * 2019-06-04 2022-07-05 Boehringer Ingelheim International Gmbh Purine derivatives and the use thereof as medicament
WO2025233259A1 (fr) 2024-05-07 2025-11-13 Boehringer Ingelheim International Gmbh Composé destiné à être utilisé dans le traitement de la dépression, d'un trouble obsessionnel compulsif, d'un trouble de stress post-traumatique et/ou d'un trouble de la personnalité borderline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
CA2443108A1 (fr) 2001-04-03 2002-10-17 Merck & Co. Inc. Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
CA2453383C (fr) * 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Derives de piperidine utilises en tant qu'antagonistes du recepteur n-methyl-d-aspartate (nmda)
AU2006322067A1 (en) * 2005-12-06 2007-06-14 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2012128582A2 (fr) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant
WO2014060398A1 (fr) * 2012-10-18 2014-04-24 F. Hoffmann-La Roche Ag Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
CA2936886A1 (fr) * 2014-02-27 2015-08-03 Merck Patent Gmbh Composes heterocycliques en tant qu'inhibiteurs du canal nav, et leurs utilisations
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
BR112018007181A2 (pt) * 2015-10-14 2018-10-16 Bristol-Myers Squibb Company antagonistas de nr2b seletivos

Also Published As

Publication number Publication date
EP3867244A1 (fr) 2021-08-25
KR102840105B1 (ko) 2025-07-31
CA3113308A1 (fr) 2020-04-23
SG11202103806VA (en) 2021-05-28
CN112888685B (zh) 2023-09-22
US20210393644A1 (en) 2021-12-23
IL282142B1 (en) 2023-12-01
WO2020079039A1 (fr) 2020-04-23
ES2940184T3 (es) 2023-05-04
DK3867244T3 (da) 2023-05-01
JP7093468B2 (ja) 2022-06-29
MX2021004418A (es) 2021-07-06
JOP20210075B1 (ar) 2024-12-22
DOP2021000069A (es) 2021-05-31
PT3867244T (pt) 2023-02-22
MA53898A (fr) 2022-01-26
AR116711A1 (es) 2021-06-02
CN112888685A (zh) 2021-06-01
US20200121691A1 (en) 2020-04-23
RS63988B1 (sr) 2023-03-31
MY205127A (en) 2024-10-03
IL282142A (en) 2021-05-31
AU2019362330B2 (en) 2024-03-28
EP3867244B1 (fr) 2023-01-18
PH12021550834A1 (en) 2021-10-04
IL282142B2 (en) 2024-04-01
HRP20230249T1 (hr) 2023-04-14
JOP20210075A1 (ar) 2023-01-30
AU2019362330A1 (en) 2021-04-08
SI3867244T1 (sl) 2023-04-28
TW202031262A (zh) 2020-09-01
CL2021000858A1 (es) 2021-10-01
TWI828779B (zh) 2024-01-11
NZ773672A (en) 2024-12-20
US20250345341A1 (en) 2025-11-13
CR20210184A (es) 2021-05-26
ECSP21027009A (es) 2021-05-31
HUE061891T2 (hu) 2023-09-28
BR112021004993A2 (pt) 2021-06-08
US11166958B2 (en) 2021-11-09
JP2022505080A (ja) 2022-01-14
SA521421756B1 (ar) 2023-02-12
UA128408C2 (uk) 2024-07-03
PL3867244T3 (pl) 2023-05-22
KR20210079325A (ko) 2021-06-29
CO2021004612A2 (es) 2021-04-30
PE20211278A1 (es) 2021-07-19
EA202191014A1 (ru) 2021-11-09
FI3867244T3 (fi) 2023-03-20
LT3867244T (lt) 2023-03-10

Similar Documents

Publication Publication Date Title
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA54231A (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA34308B1 (fr) Triazolopyridines substituées
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA38099B1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA45222B1 (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA53898B1 (fr) Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament
MA70477B1 (fr) Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA51020B1 (fr) Composés imidazopyridiniques et leur utilisation comme médicament